05/09/22 4:01 PMNasdaq : ALXO earningsclinical triallow floatALX Oncology Reports First Quarter 2022 Financial Results and Provides Clinical Development and Operational HighlightsALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today reported financial results for the first quarter ended March 31,RHEA-AIvery positive
04/12/22 7:00 AMNasdaq : ALXO managementlow floatALX Oncology Appoints Itziar Canamasas, Ph.D., to its Board of DirectorsALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced the appointment of Itziar Canamasas, Ph.D., to itsRHEA-AIvery positive
03/02/22 7:00 AMNasdaq : ALXO clinical triallow floatALX Oncology Announces First Patient Dosed in ASPEN-06, a Phase 2/3 Study of Evorpacept for the Treatment of Patients with Advanced Gastric or Gastroesophageal Junction CancerALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”), a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpointRHEA-AIvery positive
02/28/22 7:00 AMNasdaq : ALXO earningsclinical triallow floatALX Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Clinical Development and Operational Highlights and Upcoming MilestonesALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today reported financial results for the fourth quarter and year endedRHEA-AIneutral
01/27/22 5:51 PMNasdaq : ALXO low floatALX Oncology Receives U.S. FDA Orphan Drug Designation for Evorpacept for the Treatment of Patients with Gastric Cancer and Gastroesophageal Junction CancerALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that the U.S. Food and Drug Administration (“FDA”)RHEA-AIvery positive
01/10/22 6:00 AMNasdaq : ALXO low floatALX Oncology Provides Corporate Update and Highlights Key Milestones in 2022ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today provided a corporate update and highlighted key milestonesRHEA-AIpositive
01/04/22 7:00 AMNasdaq : ALXO conferenceslow floatALX Oncology to Present at the 40th Annual J.P. Morgan Healthcare ConferenceALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint pathway, today announced that Jaume Pons, Ph.D., Founder, President and ChiefRHEA-AIneutral
12/14/21 9:00 AMNasdaq : DRRX, ALXO managementDURECT Corporation Expands Board of Directors with Appointment of Biopharmaceutical Industry Finance Veteran Peter GarciaDURECT Corporation (Nasdaq: DRRX) today announced the expansion of its board of directors with the appointment of Peter García, a biopharmaceutical industry veteran with over 25 years of financial leadership experience. "We are delighted to welcomeRHEA-AIneutral
12/12/21 9:00 AMNasdaq : ALXO clinical triallow floatALX Oncology Announces Initial Data from ASPEN-02, the Ongoing Phase 1 / 2 Study of Evorpacept in Combination with Azacitidine, Demonstrating Safety and Preliminary Activity in Patients with Myelodysplastic SyndromeObjective responses were observed in patients with relapsed/refractory MDS that had progressed after prior hypomethylatingRHEA-AIneutral
11/11/21 4:05 PMNasdaq : ALXO earningsclinical triallow floatALX Oncology Reports Third Quarter 2021 Financial Results and Provides Clinical Development and Operational HighlightsALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today reported financial results for the third quarter ended SeptemberRHEA-AIpositive